Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | August 27, 2026 | August 28, 2026 |
| Phathom Pharmaceuticals, Inc.PHAT · Entity 5177 | Director · President and Chief Executive | February 27, 2025 | March 03, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date August 27, 2026 · Filed August 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,526 |
Ending reported balance
After 2026-08-27 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-27 · Exercise / conversion · Acquired 11,148 · Balance 34,674 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Row 2 · 2026-08-27 · Sale · Disposed 11,148 · Balance 23,526 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-27 · Exercise / conversion · Acquired 27,052 · Balance 50,578 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Row 4 · 2026-08-27 · Sale · Disposed 27,052 · Balance 23,526 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-27 · Exercise / conversion · Disposed 11,148 · Balance 0 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F4: The option is fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14 | Direct | 0 |
Reported balance
After 2026-08-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-27 · Exercise / conversion · Disposed 27,052 · Balance 0 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F4: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.
F4: The option is fully vested.
Phathom Pharmaceuticals, Inc.
Report date February 27, 2025 · Filed March 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2035-02-26 | Direct | 342,500 |
Reported balance
After 2025-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-02-27 · Grant · Acquired 342,500 · Balance 342,500 F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 3,426 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 1,857 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 6,593 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 4,120 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 1
1 source rowRow 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration"). |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.30 · Expires 2026-11-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-10 · Disposition to issuer · Disposed 33,846 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2027-05-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 11,154 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.14 · Expires 2027-08-17 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.25 · Expires 2028-08-30 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-10 · Disposition to issuer · Disposed 5,250 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.
F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
F4: These options are fully vested.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 31, 2019 Filed Nov 4, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,123 | $108.03 | $121,317.69 |
DisclosureSEC source: 0001415889-19-001256 · form4-11042019_041110.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,313 Read SEC document |
| October 31, 2019 Filed Nov 4, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 3,281 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001256 · form4-11042019_041110.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $58.33 | $0.00 |
DisclosureSEC source: 0001415889-19-001066 · form4-09192019_040901.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,072 Underlying: Common Stock · 4,500 shares Expires 2023-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 6,838 | $98.31 | $672,243.78 |
DisclosureSEC source: 0001415889-19-001066 · form4-09192019_040901.xml · nonDerivative · entry 3 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 4,500 | $98.20 | $441,900.00 |
DisclosureSEC source: 0001415889-19-001066 · form4-09192019_040901.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,993 Read SEC document |
| September 18, 2019 Filed Sep 19, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 4,500 | $58.33 | $262,485.00 |
DisclosureSEC source: 0001415889-19-001066 · form4-09192019_040901.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2019 Filed Aug 27, 2019 20:42 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 58,608 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001209191-19-047528 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,608 Underlying: Common Shares · 58,608 shares Expires 2029-08-22 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000507 · form4-05062019_040510.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,563 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 490 | $95.21 | $46,652.90 |
DisclosureSEC source: 0001415889-19-000507 · form4-05062019_040510.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,993 Read SEC document |
| May 02, 2019 Filed May 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 1,563 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000507 · form4-05062019_040510.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 2, 2016 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 27,749 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000247 · form4-03052019_040302.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,749 Underlying: Common Stock · 27,749 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,120 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-19-000137 · form4-02062019_040215.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,120 Underlying: Common Stock · 4,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments, beginning on February 4, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:28 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001772 · form4-12182018_031253.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:28 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 1,231 | $68.20 | $83,954.20 |
DisclosureSEC source: 0001415889-18-001772 · form4-12182018_031253.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,920 Read SEC document |
| December 16, 2018 Filed Dec 18, 2018 18:28 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001772 · form4-12182018_031253.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 16, 2015 have vested and settled for shares of the Company's common stock. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 12,983 | $0.00 Strike: $71.43 | $0.00 |
DisclosureSEC source: 0001415889-18-001566 · form4-10312018_041007.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,983 Underlying: Common Stock · 12,983 shares Expires 2028-10-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on October 29, 2019. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 20:47 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $24.25 | $0.00 |
DisclosureSEC source: 0001209191-18-049224 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2028-08-30 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 31, 2019, and (b) the date that is one day prior to the Issuer's 2019 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 12,983 | $0.00 Strike: $88.91 | $0.00 |
DisclosureSEC source: 0001415889-18-001202 · form4-08012018_040811.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,983 Underlying: Common Stock · 12,983 shares Expires 2028-07-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 30, 2019. Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 6,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-18-000760 · form4-05172018_010508.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,593 Underlying: Common Stock · 6,593 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on May 8, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| May 08, 2018 Filed May 17, 2018 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (Right to Buy) · Derivative | 12,982 | Not disclosed Strike: $83.13 | Not disclosed |
DisclosureSEC source: 0001415889-18-000760 · form4-05172018_010508.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,982 Underlying: Common Stock · 12,982 shares Expires 2028-05-08 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal installments, commencing on May 8, 2019. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:56 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000699 · form4-05082018_010519.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:56 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 856 | $86.89 | $74,377.84 |
DisclosureSEC source: 0001415889-18-000699 · form4-05082018_010519.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,651 Read SEC document |
| May 04, 2018 Filed May 8, 2018 16:56 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000699 · form4-05082018_010519.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units granted to the reporting person on May 4, 2015 have vested and settled for shares of the Company's common stock. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:39 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 6,777 | $0.00 Strike: $103.26 | $0.00 |
DisclosureSEC source: 0001209191-18-006226 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,777 Underlying: Common Stock · 6,777 shares Expires 2028-01-29 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest as follows: 1,694 shares on January 29, 2019; 1,694 shares on January 29, 2020; 1,694 shares on January 29, 2021; and 1,695 shares on January 29, 2022. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 1,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066618 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,765 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to The Celgene Corporation 2017 Stock Incentive Plan. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 683 | $107.06 | $73,121.98 |
DisclosureSEC source: 0001209191-17-066618 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,007 Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 16:03 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 1,765 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066618 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on December 19, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,857 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-058428 · doc4.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,857 Underlying: Common Stock · 1,857 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will fully vest on October 30, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| October 30, 2017 Filed Oct 31, 2017 16:09 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 15,659 | Not disclosed Strike: $100.97 | Not disclosed |
DisclosureSEC source: 0001209191-17-058428 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,659 Underlying: Common Stock · 15,659 shares Expires 2027-10-30 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments, commencing on October 30, 2018. Read SEC document |
| September 25, 2017 Filed Sep 26, 2017 16:29 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 1,727 | $143.89 | $248,498.03 |
DisclosureSEC source: 0001209191-17-053976 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,925 F1 · price: These shares were sold by the reporting person pursuant to a Rule 10b5-1 plan. Read SEC document |
| August 18, 2017 Filed Oct 20, 2017 20:45 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $13.14 | $0.00 |
DisclosureSEC source: 0001209191-17-057645 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2027-08-17 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 18, 2018, and (b) the date that is one day prior to the Issuer's 2018 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:38 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047124 · doc4.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:38 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 558 | $135.18 | $75,430.44 |
DisclosureSEC source: 0001209191-17-047124 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,652 F2 · shares: This amount reflects shares withheld by the Company for the payment of taxes on the vested shares. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 16:38 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-047124 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on August 1, 2014 vested and settled for shares of the Company's common stock. Read SEC document |
| July 31, 2017 Filed Aug 2, 2017 16:38 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 6,776 | $0.00 Strike: $135.41 | $0.00 |
DisclosureSEC source: 0001209191-17-047124 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · See remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,776 Underlying: Common Stock · 6,776 shares Expires 2027-07-31 F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F3 · derivative.exercise_date: Option is immediately exercisable and will vest in four equal annual installments commencing on July 31, 2018. Read SEC document |
| May 15, 2017 Filed May 17, 2017 21:12 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 11,154 | $0.00 Strike: $12.68 | $0.00 |
DisclosureSEC source: 0001209191-17-033234 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,154 Underlying: Common Shares · 11,154 shares Expires 2027-05-14 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on May 15, 2018; the balance of the shares vest and become exercisable in a series of eight (8) successive equal quarterly installments measured from May 15, 2018, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:30 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 33,846 | $0.00 Strike: $11.30 | $0.00 |
DisclosureSEC source: 0001209191-16-150868 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,846 Underlying: Common Shares · 33,846 shares Expires 2026-11-14 F1 · derivative.exercise_date: 1/3 of the shares underlying the option shall vest and become exercisable on November 15, 2017; the balance of the shares shall vest and become exercisable in a series of eight (8) successive equal quarterly installments measured from November 15, 2017, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.